Decongestants Global Market Report 2025

The decongestants market size has grown strongly in recent years. It will grow from $18.63 billion in 2024 to $20.39 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historic period can be attributed to the rising prevalence of the common cold, increased use of over-the-counter medications, heightened awareness of self-medication, expansion of pharmaceutical retail networks, and a growing number of allergic rhinitis cases.

The decongestants market size is expected to see strong growth in the next few years. It will grow to $28.94 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. Growth during the forecast period can be attributed to the increasing demand for combination drugs, improved healthcare access in emerging markets, a growing preference for nasal sprays, an expanding elderly population, and the rising adoption of online pharmacies. Key trends expected in this period include technological advancements in drug delivery systems, innovations in pediatric formulations, development of extended-release decongestants, research into allergy-specific treatments, and innovations in natural and herbal alternatives.

The rising incidence of allergies, colds, and sinusitis is expected to drive the growth of the decongestants market moving forward. Allergies are immune responses to harmless substances, colds are viral infections that cause respiratory symptoms, and sinusitis is inflammation of the sinuses often triggered by infections or allergies. The increase in these conditions is linked to growing air pollution and environmental irritants. Decongestants aid in managing allergies, colds, and sinusitis by relieving nasal congestion, reducing inflammation in the nasal passages, improving airflow, easing breathing difficulties, and enhancing patient comfort. For example, in December 2023, USAFacts, a US-based nonprofit organization, reported that during the 2022-2023 US flu season, about 31.9 million people experienced flu symptoms, with nearly 85% of cases occurring between October and January. Thus, the rising incidence of allergies, colds, and sinusitis is fueling growth in the decongestants market.

Leading companies in the decongestants market are focusing on expanding over-the-counter nasal decongestant offerings, such as fast-acting sprays, to provide quick and effective relief from nasal congestion, thereby improving user comfort and treatment results. A fast-acting spray is a nasal spray that offers rapid relief by quickly reducing nasal congestion soon after use. For example, in August 2024, Manx Healthcare Ltd., a UK-based pharmaceutical firm, launched the Xylometazoline Decongestant Nasal Spray as part of its strategy to grow its respiratory care portfolio. This fast-acting, over-the-counter product is specifically designed to relieve nasal congestion caused by conditions like colds, sinusitis, and allergic rhinitis. The launch highlights the company’s dedication to offering accessible, high-quality self-care treatments while meeting growing consumer demand for effective decongestants that deliver rapid, long-lasting relief with ease of use.

In October 2023, Haleon plc, a UK-based pharmaceutical company, collaborated with AptarGroup Inc. to develop a new generation of nasal sprays. This partnership aims to transform nasal congestion treatment by integrating innovative microdroplet and Lateral Control System pump technologies to provide a more comfortable, effective, and user-friendly nasal spray experience. The goal is to overcome common usage barriers and improve relief for patients suffering from colds, allergic rhinitis, and sinusitis. AptarGroup, Inc., a US-based company, specializes in designing and manufacturing drug delivery and dispensing technologies, including those for nasal decongestants.

Major players in the decongestants market are Pfizer Inc., Procter & Gamble Co., Johnson & Johnson, Bayer AG, Sanofi S.A., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Perrigo Company plc, Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Helen of Troy Limited, Prestige Consumer Healthcare Inc., Orifarm Group A/S, Pharmascience Inc., Beximco Pharmaceuticals Ltd., Reckitt Benckiser Group plc, AdvaCare Pharma, Anish Chemicals, Marinomed Biotech AG.

North America was the largest region in the decongestants market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in decongestants report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the decongestants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Decongestants are drugs used to alleviate nasal congestion caused by ailments such as the common cold, allergies, or sinus infections. They function by constricting blood vessels in the nasal passages, which reduces swelling and helps open the airways for easier breathing.

The primary forms of decongestants include tablets, capsules, nasal sprays, and other types. Tablets are solid oral medications that relieve nasal congestion by shrinking swollen blood vessels in the nasal passages. Decongestants are classified by their delivery method into topical, oral, and inhalation forms, each catering to specific needs like convenience, speed of effect, and symptom severity. These products are made using various ingredients, including synthetic decongestants that provide fast and targeted relief, as well as natural, plant-based options. Decongestants are used to treat several conditions, including seasonal allergic rhinitis, perennial allergic rhinitis, sinusitis, nasal congestion, cold and flu, and other related issues. The main end-user groups comprise pharmacies or drugstores, online retail platforms, hospitals and clinics, and supermarkets or hypermarkets.

The decongestants market research report is one of a series of new reports that provides decongestants market statistics, including the decongestants industry global market size, regional shares, competitors with the decongestants market share, detailed decongestants market segments, market trends, and opportunities, and any further data you may need to thrive in the decongestants industry. This decongestants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The decongestants market consists of sales of oral decongestants, topical or nasal decongestants, selective alpha-adrenergic agonists, and sympathomimetic amines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.